Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease
Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.
Recent articles in left column more or less in alphabetical order classified
Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
Irradiation-Radio therapy in non-Hodgkin's lymphoma and labeled with monoclonal antibodies gives significantly longer time of survival, even if previous treatments failed.
This article is a few hours worked. Lookup, translate, places etc. If you want to support us you can do so through a donation anonymous or not. Any amount is welcome no matter how small. Click here if you want to help us to keep cancer-news online We are an ANBI organization and so your donation is tax-deductible.
11 January 2012:
Interesting to mention is in addition to the information below from 2010 a review article of the approach with radio therapy-irradiation in combination with shapes of chemo and immuuntherapeutische resources including Zevalin and Bexxar and Yttrium-90: Radioimmunotherapy or Non-Disease Lymphoma: From the ' Magic Bullets ' to ' Radioactive Magic Bullets '
In the abstract state this, but click on this link for the full study report. Down state information about radio immunotherapies from 2010:
Source: Radioimmunotherapy (RIT) or lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory follicular CD20 + B-cell non-Hodgkin's lymphoma ´ s. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Disease lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation or ride. The predominant hematological toxicity complication or ride is that is usually manageable. There are ongoing trials to further define the expanding role of RIDE as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role or RIDE in treatment of non-Disease lymphoma, which is established or clinical utility and FDA approved. The mechanism of RIDE, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
27 March 2007: source: 1: Cancer. 2007 Mar 22;
When patients who repeatedly relapse of non-Hodgkin's lymphomas have gotten (B-cell) and inter alia previous treatments no longer worked (at 37% of the participating patients) get an extra treatment with radio-immunotherapy, monoclonal antibodies, with irradiation tagged their shows median lifetime considerably. The median time to recurrence or progression of the disease appeared to come in 29 months. The five-year survival went to 53% for this group of patients.
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin's lymphoma treated with yttrium 90 ibritumomab tiuxetan.
To Witzig, Molina A, Gordon LI, Emmanouilides C, Painter RJ, Flinn IW Darif, M, R, K, Wiseman Macklis Vo GO.
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Radioimmunotherapy with radiolabeled monoclonal antibodies to BACKGROUND.: CD20 produces a high response rate in patients with non-Hodgkin's lymphoma (NHL) recurring, but the durability of those remissions is not well defined.
METHODS: Data on patients with recurring yttrium Y 90 ibritumomab tiuxetan in NHL treated with 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression or 12 months or longer.
RESULTS: Long-term responses were seen in 37% (78/211) or patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n = 59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with ibritumomab tiuxetan (90) Y and 81% for long-term responders.
CONCLUSIONS: A single dose or ibritumomab tiuxetan (90) Y can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed. Cancer 2007. (c) 2007 American Cancer Society. PMID: 17380530 [PubMed-as supplied by publisher]
